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Abstract
Introduction: Hyperthyroidism is a well established cause of atrial fibrillation (AF). Thyroid Stimulating
Hormone-secreting pituitary tumours are rare causes of pituitary hyperthyroidism. Whilst pituitary causes
of hyperthyroidism are much less common than primary thyroid pathology, establishing a clear aetiology
is critical in minimising complications and providing appropriate treatment. Measuring Thyroid Stimulating
Hormone (TSH) alone to screen for hyperthyroidism may be insufficient to appropriately evaluate the
thyroid status in such cases.
Case presentation: A 63-year-old Caucasian man, previously fit and well, presented with a five-day
history of shortness of breath associated with wheeze and dry cough. He denied symptoms of
hyperthyroidism and his family, social and past history were unremarkable. Initial investigation was in
keeping with a diagnosis of atrial fibrillation (AF) with fast ventricular response leading to cardiac
decompensation.
TSH 6.2 (Normal Range = 0.40 – 4.00 mU/L), Free T3 of 12.5 (4.00 – 6.8 pmol/L) and Free T4 51(10–30
pmol/L). Heterophilic antibodies were ruled out. Testosterone was elevated at 43.10 (Normal range:
10.00 – 31.00 nmol/L) with an elevated FSH, 18.1 (1.0–7.0 U/L) and elevated LH, 12.4 (1.0–8.0 U/L).
Growth Hormone, IGF-1 and prolactin were normal. MRI showed a 2.4 cm pituitary macroadenoma.
Visual field tests showed a right inferotemporal defect.
While awaiting neurosurgical removal of the tumour, the patient was commenced on antithyroid
medication (carbimazole) and maintained on this until successful trans-sphenoidal excision of the
macroadenoma had been performed. AF persisted post-operatively, but was electrically cardioverted
subsequently and he remains in sinus rhythm at twelve months follow-up off all treatment.
Conclusion: This case reiterates the need to evaluate thyroid function in all patients presenting with atrial
fibrillation. TSH-secreting pituitary adenomas must be considered when evaluating the cause of
hyperthyroidism. Early diagnosis and treatment of such adenomas is critical in reducing neurological and
endocrine complications.
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Introduction
Atrial fibrillation (AF) is a common arrhythmia associated
with increased morbidity and mortality [1] and its associ-
ation with hyperthyroidism is well documented [2]. Thy-
roid function tests to exclude hyperthyroidism are part of
the clinical assessment of patients presenting with AF [1].
However, the optimum method to assess thyroid function
is not clearly defined. Measurement of Thyroid Stimulat-
ing Hormone (TSH) alone as a 'screening test' may result
in the misdiagnosis of patients with pituitary causes of
hyperthyroidism [3].
TSH-secreting pituitary tumours (TSHomas) are rare
causes of hyperthyroidism where there is stimulation of
the thyroid gland by TSH resulting in thyroid over-activity
[4]. Failure to diagnose these correctly and inadvertent
thyroid ablation in the case of TSHomas can result in
tumour enlargement with neurological and endocrine
complications [4]. Clinical features of hyperthyroidism
are usually present at diagnosis; sometimes these are
milder than expected given the level of thyroid hormones
and also perhaps due to the longstanding duration of the
hyperthyroidism. Acute presentation is uncommon [5].
Case presentation
A 63-year-old Caucasian man, previously fit and well, pre-
sented with a five-day history of shortness of breath asso-
ciated with wheeze and dry cough. His symptoms had
progressively become worse, limiting his exercise toler-
ance. He denied symptoms of hyperthyroidism such as
heat intolerance or weight loss and reported no palpita-
tions or chest pain. His past history was unremarkable
with no history of ischaemic heart disease or diabetes and
he was taking no regular medications. He lived independ-
ently at home with his wife, working six days a week and
had stopped smoking 30 years ago. His systemic enquiry
and family history were unremarkable.
Clinical examination
The patient had tachycardia, irregularly irregular, at 122/
min with a raised jugular venous pressure (JVP) and a res-
piratory rate of 24/minute. He had no peripheral oedema
or cyanosis. Cardiovascular auscultation revealed a soft
mitral murmur. Baseline full blood count, electrolytes and
renal function were normal. Chest X-ray showed cardi-
omegaly, pulmonary congestion and a small right pleural
effusion.
Initial diagnosis
A diagnosis of Atrial Fibrillation (AF) with fast ventricular
response was made and the patient was given intravenous
diuretics and digoxin and anticoagulation was com-
menced with Low Molecular Weight Heparin. Despite 48
hours of treatment, the tachycardia persisted and the JVP
remained elevated. Echocardiogram, though limited by
tachycardia, showed no impairment of ventricular func-
tion.
Investigations
Thyroid Function Tests showed TSH 6.2 (Normal Range =
0.40 – 4.00 mU/L), Free T3 of 12.5 (4.00 – 6.8 pmol/L)
and Free T4 51(10–30 pmol/L). Repeat Thyroid Function
Tests showed TSH 6.6, Free T4 57 and Free T3 19.4 con-
firming a pituitary cause for hyperthyroidism. Retesting at
a second laboratory corroborated these values. Heter-
ophilic antibodies, which can interact with immu-
noassays, were ruled out. Pituitary function tests showed
testosterone levels were elevated at 43.10 (Normal range:
10.00 – 31.00 nmol/L) along with elevated FSH, 18.1
(Normal range: 18.1 U/L) and elevated LH at 12.4
(1.0–8.0 U/L). Growth Hormone (GH), IGF-1 and prolac-
tin were normal.
An MRI of the brain showed a pituitary macroadenoma,
2.4 cm in diameter, abutting the optic chiasm, deviating
the pituitary infundibulum and internal carotid artery.
Visual field tests showed a defect in the right inferotempo-
ral field with a normal field on the left. (Figure 1)
The patient was commenced on warfarin, but his Interna-
tional Normalised Ratio (INR) estimating his control on
warfarin was markedly elevated with loading doses of
warfarin and required reversal of anticoagulation with
Vitamin K and introduction of low molecular weight
heparin.
Treatment and management
The patient was diagnosed as having a TSHoma and a
decision was made to attempt neurosurgical removal. He
was commenced on antithyroid medication (carbima-
zole) in the interim. Attempts to wean down his carbima-
zole resulted in an escalation of his symptoms and he was
therefore maintained on this until successful trans-sphe-
noidal excision of his pituitary macroadenoma had been
performed.
His AF persisted post-operatively, but was electrically car-
dioverted and he remains in sinus rhythm at twelve
months follow-up off all treatment.
Outcome
Post-operative MRI showed near total removal of the pitu-
itary adenoma. (Figure 2) Histology showed positive
staining for GH, Prolactin and TSH. His TSH and T4 levels
have remained normal post-operatively and glucagon
stimulation test demonstrated adequate cortisol and GH
response. His testosterone levels have also normalised
after a transient fall post-operatively. GH, Prolactin and
IGF-1 levels remained normal. FSH is persistently slightly
raised at 9.1 U/L (1.0–7.0). The patient is asymptomatic,Journal of Medical Case Reports 2008, 2:67 http://www.jmedicalcasereports.com/content/2/1/67
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needing no treatment and back at full time employment.
Arrangements are in place for a follow-up pituitary MRI.
Discussion
TSH producing tumours of the pituitary are usually large
tumours and they usually cause enlargement of the thy-
roid gland. Despite this however, overt thyrotoxicosis is
uncommon, possibly due to a reduction in the biological
activity of the secreted TSH. This case illustrates that
although uncommon and thought to present with insidi-
ous symptoms, TSH secreting pituitary tumours (TSHo-
mas) can occasionally present with acute manifestations
like rapid atrial fibrillation and cardiac decompensation.
The majority of TSHomas (72%) secrete TSH alone, but
16% also secrete growth hormone (GH), 11% secrete pro-
lactin (PRL), and 1% secretes LH or FSH [6]. The elevation
in serum testosterone levels in our patient was secondary
to co-secretion of LH and FSH by the adenoma. This illus-
trates the need to systematically assess complete pituitary
function in such patients especially as some pituitary ade-
nomas express positive histological staining for hormones
without corresponding biochemical hyper-secretion [7].
Thyroid hormone concentrations can influence the meta-
bolic rates of proteins and thus can alter the amount of
vitamin K-dependent clotting factors, which in turn can
alter the sensitivity to warfarin [8,9]. This may lead to
changes in anticoagulation, increasing the risk of throm-
boembolic or hemorrhagic events. The volatile response
to warfarin treatment in our patient stabilised with correc-
tion of his hyperthyroidism. Patients with AF associated
with hyperthyroidism therefore need close monitoring of
their anticoagulation profile.
It is critical to distinguish central hyperthyroidism from
the more common types of primary hyperthyroidism.
Measuring TSH alone as a 'screening test' may result in
misdiagnosis of patients with TSHomas. Elevated Free T4
and/or T3 levels with a normal (non-suppressed) TSH
should trigger investigations looking for a pituitary cause
as inadvertent thyroid ablation resulting from such misdi-
agnosis can result in enlargement of these tumours [4].
Assay cross reactivity, presence of heterophilic antibodies
and pituitary resistance to thyroid hormones are the three
MRI of Pituitary – on admission Figure 1
MRI of Pituitary – on admission.
MRI of Pituitary – post operative Figure 2
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important alternatives to be considered. Assessment of
TSH alpha subunit and TRH stimulation tests can help in
differentiating TSHomas from pituitary and peripheral
resistance to thyroid hormones. These tests were consid-
ered in our case but not performed as the diagnosis was
adequately established from the available biochemistry
and radiological appearance. We feel that further testing
would not have contributed further in the evaluation of
our patient but accept that it often can be useful in the
diagnostic work up of such cases.
Conclusion
Elevated Free T4 and/or T3 levels with a normal (non-sup-
pressed) TSH should trigger a thorough investigation
process looking for a pituitary cause of hyperthyroidism.
In pituitary hyperthyroidism, complete pituitary function
tests help identify pituitary adenomas that co-secrete
other hormones along with TSH. Early diagnosis and
treatment of TSH-secreting adenomas is critical in avoid-
ing the neurological and endocrine complications that
can result especially when misdiagnosed as primary
hyperthyroidism and treated with radioiodine ablation.
This case also highlights the need to evaluate thyroid func-
tion in all patients presenting with atrial fibrillation. Pres-
entation of TSH-secreting pituitary adenomas with acute
cardiac decompensation is uncommon, but prompt man-
agement of the underlying hyperthyroidism is critical to a
successful outcome.
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